PetVivo (PETV) investor relations material

Market opportunity and industry trends

• US companion animal veterinary care and product sales market valued at $39.8B, with a ~6% CAGR from 2020-2024.

• Pet ownership and spending are rising, with 71% of US households owning pets and pet insurance adoption increasing rapidly.

• Market demand is shifting toward more effective, natural medical devices and therapeutics.

Product portfolio and innovation

• SpryngⓇ with OsteoCushion® Technology is a regenerative veterinary device for joint afflictions, mimicking natural cartilage and providing up to 12+ months of benefit per injection.

• PrecisePRP™ is an off-the-shelf, FDA-reviewed, freeze-dried platelet-rich plasma product for intra-articular use in animals.

• Strong IP portfolio with 12 US and foreign patents and 6 proprietary trade secrets.

• Strategic partnerships drive innovation, including collaborations in functional biomaterials and AI pet care ecosystems.

Clinical evidence and competitive advantages

• SpryngⓇ addresses the root cause of osteoarthritis, not just symptoms, with natural biomaterials and no pharmacological action.

• Clinical studies and case reports show significant improvements in mobility and pain reduction in dogs and horses.

• Tolerance studies in dogs and cats confirm an excellent safety profile.

• Over 12,000 animals have been successfully treated with SpryngⓇ.

• Competitive advantages include cost, ease of application, and vet clinic exclusivity.